Corporate ActionJul 8, 2026, 04:38 PM
Regentis Biomaterials Registers 3.8M Shares for Resale by Shareholders
AI Summary
Regentis Biomaterials Ltd. filed an F-1 registration statement for the resale of up to 3,807,143 Ordinary Shares by selling shareholders. These shares were issued in a private placement completed on June 17, 2026, which included Ordinary Shares and various warrants. While the company will not receive proceeds from the resale, it could receive approximately $8.21 million if all warrants are exercised for cash, which would be used for Gelrin platform development and clinical studies. The company also provided an update on its GelrinC pivotal trial, noting 47 of 80 patients recruited and 43 completing two-year follow-up.
Key Highlights
- Regentis Biomaterials registered 3,807,143 Ordinary Shares for resale by selling shareholders.
- Shares originated from a private placement completed on June 17, 2026.
- Private placement included 1,844,543 Ordinary Shares and warrants for 1,869,743 shares.
- Company will not receive proceeds from the resale of shares by selling shareholders.
- Potential proceeds of $8.21 million if all Offered Warrants are exercised for cash.
- Pro forma cash and cash equivalents increased to $11.161 million as of December 31, 2025.
- GelrinC pivotal trial has recruited 47 of 80 patients, with 43 completing two-year follow-up.
Price Impact
More from RGNT